JAKAFI vs RINVOQ

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 21, 2026·How we rate

Possible drug interaction. JAKAFI and RINVOQ are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	JAKAFI	RINVOQ
Rating	New	72/100
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	RUXOLITINIB PHOSPHATE	UPADACITINIB
Manufacturer	Incyte Corp	Abbvie
Dosage forms	Tablet	Solution, Tablet, extended release
Drug class	Janus Kinase Inhibitor	Janus Kinase Inhibitor
Boxed warning	None	Boxed warning
Half-life	—	about 8 to 14 hours (mean terminal elimination half-life)
Treats	Polycythemia Vera, Primary Myelofibrosis	Rheumatoid Arthritis

jakafi rinvoq

Rating

New

72/100

Pharmacy pays

—

Type

Active ingredient

RUXOLITINIB PHOSPHATE

UPADACITINIB

Manufacturer

Incyte Corp

Abbvie

Dosage forms

Tablet

Solution, Tablet, extended release

Drug class

Janus Kinase Inhibitor

Boxed warning

None

Boxed warning

Half-life

—

about 8 to 14 hours (mean terminal elimination half-life)

Treats

Polycythemia Vera, Primary Myelofibrosis

Rheumatoid Arthritis

Frequently asked questions

What is the difference between Jakafi and Rinvoq?

Jakafi contains Ruxolitinib Phosphate, while Rinvoq contains Upadacitinib — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.